Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top

Investigational New Drugs

Issue 4/2023

Content (10 Articles)

Open Access Breast Cancer Research

Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells

Minhong Tang, John Crown, Michael J Duffy

Melanoma Research

A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma

Elizabeth I. Buchbinder, Anita Giobbie-Hurder, Rizwan Haq, Patrick A. Ott

NSCLC Research

POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma

Yongzhao Li, Qidong Yang, Yaqin Liu, Huan Yi, Yongzhi Ju, Guoyan Qi

Glioblastoma Research

Sitravatinib is a potential EGFR inhibitor and induce a new death phenotype in Glioblastoma

Hanwen Lu, Bingchang Zhang, Yuanyuan Xie, Wenpeng Zhao, Wanhong Han, Liwei Zhou, Zhanxiang Wang

Gastric Cancer Research

Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study

Xue Wang, Jinxiang Huang, He Huang, Yang Liu, Chao Ji, Jian Liu

Pancreatic Cancer Research

The p53 reactivator PRIMA-1MET synergises with 5-fluorouracil to induce apoptosis in pancreatic cancer cells

Ibtehal Mohammed, Ali Haider Alhammer, Inam Sameh Arif

Open Access Dabigatran Research

Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates

Özkan Yalkinoglu, Andreas Becker, Axel Krebs-Brown, Claudia Vetter, Christian Lüpfert, Dominique Perrin, Jürgen Heuer, Herlind Biedert, Stefan Hirt, Afrim Bytyqi, Angelika Bachmann, Rainer Strotmann

Open Access Zanubrutinib Research

Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma

Yuqin Song, Keshu Zhou, Shenmiao Yang, Jianda Hu, Dehui Zou, Sujun Gao, Ling Pan, Tingyu Wang, Haiyan Yang, Huilai Zhang, Daobin Zhou, Jie Ji, Wei Xu, Ru Feng, Jie Jin, Fangfang Lv, Haiwen Huang, Xiaosi Fan, Sheng Xu, Jun Zhu

Hepatocellular Carcinoma Research

Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study

Chenghao Zhao, Huzheng Yan, Zhanwang Xiang, Haofan Wang, Mingan Li, Mingsheng Huang

Kidney Cancer Correction

Correction to: The kinesin motor protein KIF4A as a potential therapeutic target in renal cell carcinoma

Guihong Liu, Yachun Lu, Liantao Li, Tao Jiang, Sufang Chu, Pingfu Hou, Jin Bai, Ming Chen

Jun 23
Issue: 3/2023
Oct 23
Issue: 5/2023

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits